EyeGate Pharmaceuticals has completed enrollment in a phase 2 proof-of-concept study investigating PP-001 in patients with ocular surface inflammation, according to a press release.
Twenty-one patients in Austria were enrolled in the randomized, double-masked, placebo-controlled study, which is designed to investigate the safety, tolerability and efficacy of PP-001 in patients with ocular surface inflammation due to dry eye disease. Patients are being treated with PP-001 0.15% or placebo for 12 days.
“We believe our proof-of-concept study will further validate the clinical utility of